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EDITORIAL

Pyridoxine Dependent Epilepsy:
Enduring Mystery and Continuing
Challenges

Can J Neurol Sci. 2012; 39: 411-412

Since the initial description of seizures that were responsive
to vitamin B6 (pyridoxine) supplements in 1954 (Hunt 1954),
the disorder and its biochemical pathogenesis remained a
mystery for nearly half a century1. In the intervening five
decades, the published medical literature is replete with case
reports providing detailed clinical descriptions and much
speculation regarding potential mechanisms underlying this
intriguing disorder2-6.
The paper by Alfadhel et al in this issue of the Journal is a
timely reminder to neurologists and paediatricians alike of the
current state of our understanding of pyridoxine dependent
epilepsy (PDE) and the continuing challenges to the effective
management of this disorder7. The authors describe the variable
presentation in two siblings sharing the same mutations, and
treated with pyridoxine since early infancy. Despite excellent
control of their epileptic seizures the two differed in their
cognition and intellectual outcomes significantly.
Pyridoxine dependent epilepsy merits greater interest from
the academic community as well as clinicians to further
understand the wider implications of this condition.
Firstly, it is useful to examine what is known about the
condition. The clinical presentation of this disorder is highly
variable and the symptoms are not necessarily restricted to the
nervous system. Seizures may begin within the first month of life
(early onset classical PDE), or in atypical forms as late as two
years. Recognition in the neonatal period can be, easier if
seizures are the primary presentation but particularly challenging
if there are multisystem features that may often be mistaken for
sepsis8,9. Until the end of the last century, the diagnosis could
only be made if the disorder was considered by the treating
clinician, and empirical treatment was initiated. This was more
likely if the presentation was in the neonatal period with seizures
when a pyridoxine trial was initiated as part of a standard
protocol followed in most neonatal units.
In the last decade, rapid progress has been made with the
recognition of the biochemical markers pipecolic acid (plasma
and CSF) and L-α-aminoadipic semialdehyde (AASA) (plasma,
CSF and urine). The assay for urinary AASA has been
considered until now to be a reliable marker for PDE, and it is
valuable to know that its excretion continues to be elevated
whether or not the patient is on treatment with pyridoxine
supplements. Thus, treatment need not be deferred or withdrawn
for the fear of interference with the assay10.
Confirmation of the diagnosis of PDE can now be established
with certainty by the identification of pathogenic mutations in
ATQ coding for α-aminoadipic-semialdehyde hydrogenase
(ALDH7A or antiquitin)11-13. Recent data suggests that urinary
AASA may also be elevated in molybdenum co-factor and sulfite
oxidase deficiency, suggesting that both the urinary AASA assay
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and molecular confirmation of a pathogenic mutation in the
antiquitin gene are necessary for a confirmed diagnosis of
PDE14. Further, the condition of “folinic acid dependent
epilepsy” is now established to be an allelic condition to PDE, as
patients diagnosed with the former condition have also been
shown to carry mutations in ATQ15. A cautionary footnote is the
overlap of PDE related to ALDH7A deficiency and pyridoxine5’-phosphate oxidase (PNPO) deficiency based on plasma amino
acid and amine profiles in the CSF16. This diagnostic confusion
may arise, as several of the symptoms reported may be due to
secondary deficiencies in pathways dependent on pyridoxal
phosphate. Thus, urinary AASA measurement needs to be carried
out to differentiate between ALDHA7 and PNPO deficiencies.
So why do neurologists need to be aware of these disorders?
It is possible that the PDE may not have been in the diagnostic
considerations in adults with refractory epilepsy. This would
now be important, particularly if the patient history indicates that
the epilepsy had an early onset and/or the patient never had a
pyridoxine trial. Many cases in adults are attributed to a static
encephalopathy if there is a structural lesion on imaging, and we
are learning that this should not preclude a diagnosis of PDE8.
The diagnosis once established would no doubt lead to improved
seizure control with initiation of treatment with pyridoxine.
The report highlights a particular area of concern, that the
intellectual outcome may remain compromised despite early
institution of therapy. Contrary to this notion is the evidence in
published literature of patients in whom documented treatment
delay was associated with normal cognition. This raises
additional questions about the relationship between institution of
pyridoxine treatment and cognitive/neurological outcomes. It is
not clear whether the effects of pyridoxine deficiency are
prenatal, perinatal or postnatal in timing. Furthermore it is not
known whether the secondary deficiencies in neurotransmitter
metabolism as demonstrated on CSF amine profiles also merit
treatment and whether dietary modifications such as lysine
restriction will provide added benefit. The patients described in
the published report are compound heterozygotes for two known
pathogenic mutations (c. 1195G>C (p.107 Glu399Gln) and
c.1429G>C(p. Gly477 Arg).The genotype-phenotype correlations
in PDE are still not clearly established and likely to be complex.
Genetic counseling needs to be provided to the families of
affected patients.
Moving forward, what are the next steps in seeking to further
understanding and clarification around these questions? It is
necessary that the assays for urinary AASA and molecular
testing for mutations in the antiquitin gene be available for
clinicians to access for their patients with suspected diagnosis of
PDE. Developing such assays in reference laboratories across the
country is a priority. A nationwide registry needs to developed
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and implemented where data regarding suspected and confirmed
clinical cases are collected. A registry requires time and
resources to be maintained but is one way forward in evaluating
the critical questions that remain to be answered; what is the
relationship between genotype and phenotype in patients with
PDE, is there a temporal relationship between timing of
treatment and intellectual outcome, what is the correct dose of
pyridoxine supplementation, and how long should it be
continued safely? A registry would provide estimates of the
prevalence of this disorder and permit patients to participate in
multicenter clinical trials using standardized protocols. We need
to know if AASA has sufficient stability, sensitivity and
specificity for PDE to propose incorporation into newborn
screening programs so that diagnosis and intervention may be
achieved in the presymptomatic stage, as is the case with other
disorders such as phenylketonuria where early interventions
have a very significant impact on outcomes.
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